Moreover, the recently published results of a clinical trial conducted in patients with triple-negative breast cancer (TNBC) demonstrated that low levels of DOX resulted in tumor microenvironment alterations that enhanced the sensitivity of the tumor to anti-PD-1 and PD-L1 treatments. The gene discussed is CD274; the disease is neoplasm.